Well, Right-to-Try has not even been implemented yet. The FDA could easily take another year to enact the enabling regulations.
Second,the law says the company must still abide by the rules on charging for unapproved drugs. As of now, this states direct cost recovery. So other than perhaps offsetting some of S Goldman's salary, all they can do is pass the revenue on to Cognate who incurs all the cost.
They are getting suprising late for a cash raise though. There last $1M raise was on June 22, even if they still had $2M in the bank then they should be at $0 now.